


PHARMACEUTICAL 2022

Silverback Therapeutics Inc. Rank 152 of 475





PHARMACEUTICAL 2022

Silverback Therapeutics Inc. Rank 152 of 475

The relative strengths and weaknesses of Silverback Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Silverback Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 105% points. The greatest weakness of Silverback Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is -11%, being 266% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	261,492
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,892
Liabilities, Non-Current	4,760
Other Assets	69,763
Other Compr. Net Income	-326
Other Expenses	0
Other Liabilities	0
Other Net Income	106
Property and Equipment	2,212
Research and Development	61,501
Revenues	0
Selling, General and Administrative Expense	28,083

Output Variable	Value in 1000 USD
Assets	333,467
Liabilities	19,652
Expenses	89,584
Stockholders Equity	313,815
Net Income	-89,478
Comprehensive Net Income	-89,641
Economic Capital Ratio	-11%